<DOC>
	<DOC>NCT00623519</DOC>
	<brief_summary>To investigate the global incidence of the endometrial changes in postmenopausal women receiving Anastrozole for the adjuvant treatment of hormone receptors positive breast cancer.</brief_summary>
	<brief_title>Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Provision of Informed Consent Resectable breast cancer patients, with histological confirmation Patients eligible to receive hormonal adjuvant treatment with Anastrozole They are allowed patients treated with adjuvant chemo or radiotherapy concurrently Patients previously treated with Tamoxifen that had to withdraw treatment due to other reason than endometrial changes are allowed Postmenopausal patients(aged 50 years or over/ without menses in the last months/ FSH level &gt;40UI/L / women under 50 years with FSH levels&gt;40UI/L). Women showing progesterone and/or estrogen receptors positive. Patients with evidence of metastatic disease Patients unsuitable to receive the medication according the Anastrozole label Patients not giving their Informed Consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Adjuvant postmenopausal breast cancer women</keyword>
</DOC>